Scienture secures formulary coverage for Rezenopy with national health plan
Scienture Holdings Inc. secured formulary coverage for Rezenopy with a large national health plan, extending access to over 100 million lives. The U.S. naloxone market totals approximately $144 million in annual sales. The company expanded its commercial team and secured GPO agreements covering over 5,000 facilities.
*this image is generated using AI for illustrative purposes only.
Scienture Holdings Inc. has added its opioid overdose treatment Rezenopy (naloxone HCl) Nasal Spray 10 mg to the formulary of a large national health plan, broadening commercial and Medicare supplemental coverage ahead of the product's planned mid-July 2026 launch. This addition increases potential access to more than 100 million covered lives across the U.S., marking a significant step in the company's commercialization strategy. Rezenopy is the highest FDA-approved naloxone dose per nasal spray available in the U.S., delivering 10 mg of naloxone hydrochloride for the emergency treatment of known or suspected opioid overdose.
Market Opportunity
According to IQVIA data for the 12 months ended April 2026, the U.S. naloxone market presents a substantial commercial opportunity. The following table outlines the key market metrics:
| Metric | Value |
|---|---|
| Annual Sales | ~$144 million |
| Annual Units | ~9.8 million |
Commercial Rollout Strategy
Scienture is pursuing a multi-channel commercialization strategy targeting institutional, government, and commercial customers. To support the nationwide launch, the company recently expanded its commercial organization by adding three sales representatives focused on driving adoption across institutional and commercial markets. This expansion builds upon previously announced Group Purchasing Organization (GPO) agreements secured in March 2026, which provide commercial access for Rezenopy across more than 5,000 healthcare facilities and create the potential to reach over 60% of the U.S. institutional naloxone market.
Intellectual Property and Leadership
Executive Chairman and co-CEO Shankar Hariharan highlighted that the product enters a large and expanding market with a differentiated profile. In January, the United States Patent and Trademark Office issued a U.S. Patent covering Rezenopy. The patent is effective January 6, 2026, with an expiry date of February 5, 2041.
How will Scienture differentiate Rezenopy's marketing strategy to capture market share from established lower-dose naloxone competitors?
What specific pricing strategies will Scienture employ to secure favorable reimbursement rates from the remaining commercial and government payers?
To what extent does the 2041 patent expiry protect Rezenopy from potential generic competition or biosimilar entry in the near term?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
